At ECR 2026, Bayer highlighted its expansion into molecular imaging following the acquisition of two investigational radiodiagnostic agents from clinical-stage biopharmaceutical company Attralus.
The assets are designed to support the detection of cardiac amyloidosis, a disease that is often under-recognized and difficult to diagnose. According to the company, current diagnostic approaches are either non-specific or require invasive procedures such as endomyocardial biopsy.
The new tracers aim to provide a non-invasive and disease-specific diagnostic option, potentially enabling clinicians to identify cardiac amyloidosis earlier and guide patients to appropriate therapies more quickly.
Erin Bowman, Senior Director of Molecular Imaging and Theranostics for US and Global, noted that molecular imaging complements its existing radiology portfolio, which includes contrast media and injection systems. The company sees targeted radiodiagnostics as an important component of the growing shift toward precision medicine and more specific disease characterization.
